Get started
Author

Cédric Barrière

Observed names: C. Barrière, Cedric Barriere, Cédric Barrière
Observed institutions: Centre National de la Recherche Scientifique, Université de Bordeaux, Sanofi (France), Spanish National Cancer Research Centre, Biologie cellulaire et Cancer, Institut Curie
OpenAlex ID: A5111484707
Cdk1 is sufficient to drive the mammalian cell cycle
2007 · David Santamaría, Cédric Barrière, et al. · Nature · 1,115
SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
2014 · Shaomeng Wang, Wei Sun, et al. · Cancer Research · 323
PDF
Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut
2014 · Maia Chanrion, Inna Kuperstein, et al. · Nature Communications · 134
PDF
Mice thrive without Cdk4 and Cdk2
2007 · Cédric Barrière, David Santamaría, et al. · Molecular Oncology · 124
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2015 · Kate Lynn J. Bill, Jeannine Garnett, et al. · Clinical Cancer Research · 105
Discovery of (2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: A Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors
2014 · Benoit Pasquier, Youssef El-Ahmad, et al. · Journal of Medicinal Chemistry · 93
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
2018 · Minjee Kim, Daniel J. Ma, et al. · Molecular Cancer Therapeutics · 39
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment
2021 · Hélène Bonnevaux, Stephane Guerif, et al. · OncoImmunology · 16
PDF
Abstract LB-204: Highly potent and optimized small-molecule inhibitors of MDM2 achieve complete tumor regression in animal models of solid tumors and leukemia.
2011 · Shaomeng Wang, Wei Sun, et al. · Cancer Research · 3
Abstract 4648: In vitro characterization of spiro-oxindole-based modulators of the MDM2-p53 interaction and their interspecies selectivity.
2012 · Christine Delaisi, Isabelle Meaux, et al. · Cancer Research · 1
Supplemental Figures S1-S7 from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
2023 · Minjee Kim, Daniel J. Ma, et al.
Data from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
2023 · Minjee Kim, Daniel J. Ma, et al.
Supplemental Figures S1-S7 from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
2023 · Minjee Kim, Daniel J. Ma, et al.
PDF
Data from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
2023 · Minjee Kim, Daniel J. Ma, et al.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
2023 · Kate Lynn J. Bill, Jeannine Garnett, et al.
Works count: 39
Citation count: 1,953
H-index: 8
I10-index: 8
Year
Topic
Type